Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Sussex Hospitals NHS Foundation Trust, Chichester, UK. 6 Colorectal surgery, Raigmore Hospital, Inverness, UK. 7 Gastroenterology, Cardiff and Vale NHS Trust, Cardiff, UK. 8 Histopathology, Nottingham University Hospitals, Nottingham, UK. 9 Family History of BowelCancer Clinic, West Middlesex University Hospital, London, UK. 10 Imperial College, London, UK. 11 Histopathology, University College London, London, UK. 12 Centre for Medical Imaging, UCL, London, UK. 13 Endoscopy, St Marks Hospital (...) Abstract These consensus guidelines were jointly commissioned by the British Society of Gastroenterology (BSG), the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and Public Health England (PHE). They provide an evidence-based framework for the use of surveillance colonoscopy and non-colonoscopic colorectal imaging in people aged 18 years and over. They are the first guidelines that take into account the introduction of national bowelcancer screening. For the first time, they also
repair genes in hereditary nonpolyposis colorectalcancer patients with small bowelcancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clinical Cancer Res 2006; 12: 3389–3393  Rodriguez-Bigas MA, Vasen HF, Lynch HT et al. Characteristics of small bowelcarcinoma in hereditary nonpolyposis colorectal carci- noma. International Collaborative Group on HNPCC. Cancer 1998; 83: 240–244  SchulmannK,BraschFE,KunstmannEetal.HNPCC-associatedsmall bowelcancer (...) cancer mortality in first- degree relatives ofearly-onset colorectalcancer cases. Dis Colon Rectum 2002; 45: 681–686  Kune GA, Kune S, Watson LF. The role of heredity in the etiologyof largebowelcancer: data from the Melbourne ColorectalCancer Study. World J Surg 1989; 13: 124–129 ; discussion 9–31  Samadder NJ, Smith KR, Hanson H et al. Increased riskofcolorectal canceramongfamilymembersofallages,regardlessofageofindex case at diagnosis. Clin Gastroenterol Hepatol 2015; 13: 2305–2311
Investigating the Effect of Self-Care Training on Life Expectancy and Quality of Life in Patients with GastrointestinalCancer under Radiotherapy. A huge amount of the efforts made by health teams is dedicated to caring for cancer patients. This study has aimed to investigate the effect of self-care training on life expectancy and quality of life (QOL) in patients with gastrointestinalcancer who were under radiotherapy.In this clinical trial, 50 patients were selected using the block (...) training improved the QOL and life expectancy of patients with gastrointestinalcancer who were under radiotherapy. Therefore, self-care training is recommended to improve the QOL and the life expectancy of cancer patients.
Have inflammatory boweldisease Have hereditary syndromes that increase the risk of colorectalcancer, such as Lynch syndrome and familial adenomatous polyposis. Several factors influence individuals’ decisions whether to be screened, even when they are presented with the same information: Variation in an individual’s values and preferences A close balance of benefits versus harms and burdens (for example, for a baseline risk of 3%, FIT every two years results in five fewer deaths from colorectal (...) recommendations: an international comparison of high income countries . NHS. Bowel scope screening. . Navarro M , Nicolas A , Ferrandez A , Lanas A . Colorectalcancer population screening programs worldwide in 2016: An update . Levin TR , Corley DA , Jensen CD , et al . Effects of organized colorectalcancer screening on cancer incidence and mortality in a large community-based population . Cancer Research UK. Bowelcancer incidence statistics. . Danckert B FJ, Engholm G, Hansen HL, et al. NORDCAN: Cancer
Bevacizumab (Zirabev) - colorectalcancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity
for colonoscopies performed under the NHS bowelcancer screening programme (593/16 640, 3.6%), while they were higher for those conducted by non-NHS providers (187/2009, 9.3%). Rates were higher in women, in older age groups, and in people with inflammatory boweldisease or diverticular disease, in those with higher comorbidity scores, and in people with previous cancers. Substantial variation in rates among colonoscopy providers remained after adjustment for case mix.Wide variation exists in PCCRC-3yr rates (...) across NHS colonoscopy providers in England. The lowest incidence was seen in colonoscopies performed under the NHS bowelcancer screening programme. Quality improvement initiatives are needed to address this variation in rates and prevent colorectalcancer by enabling earlier diagnosis, removing premalignant polyps, and therefore improving outcomes.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group
Screening for ColorectalCancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. The purpose of this guidance statement is to guide clinicians on colorectalcancer screening in average-risk adults.This guidance statement is derived from a critical appraisal of guidelines on screening for colorectalcancer in average-risk adults and the evidence presented in these guidelines. National guidelines published in English between 1 June 2014 and 28 May (...) should screen for colorectalcancer in average-risk adults between the ages of 50 and 75 years.Clinicians should select the colorectalcancer screening test with the patient on the basis of a discussion of benefits, harms, costs, availability, frequency, and patient preferences. Suggested screening tests and intervals are fecal immunochemical testing or high-sensitivity guaiac-based fecal occult blood testing every 2 years, colonoscopy every 10 years, or flexible sigmoidoscopy every 10 years plus
Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinalcancer (EUFURO study) Upper gastrointestinalmalignancies have a poor prognosis. There is no consensus on how patients should be followed after surgery. The authors hypothesized that a structured follow-up programme including endoscopic ultrasonography (EUS) and [18 F]fluorodeoxyglucose (FDG) PET/CT would detect cancer recurrences, leading (...) chemotherapy (P = 0·028). Although survival after detection of recurrence in asymptomatic patients was significantly longer than that for symptomatic patients (P < 0·001), overall survival from date of surgery in the two treatment groups was comparable.Follow-up after surgery for upper gastrointestinalcancer with EUS and PET/CT leads to detection of more asymptomatic cancer recurrences and patients referred for treatment without prolonging overall survival. Registration number: NCT02209415 ( http
Colorectalcancer. Several decades ago, colorectalcancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectalcancer. Advancements in pathophysiological understanding have increased the array of treatment options for local and advanced disease (...) leading to individual treatment plans. Treatments include endoscopic and surgical local excision, downstaging preoperative radiotherapy and systemic therapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metastases, and palliative chemotherapy, targeted therapy, and immunotherapy. Although these new treatment options have doubled overall survival for advanced disease to 3 years, survival is still best for those with non-metastasised disease. As the disease
Colorectalcancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. To estimate benefits and harms of different colorectalcancer screening strategies, stratified by (baseline) 15-year colorectalcancer risk.Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon).A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection (...) of outcome measures.Norwegian men and women aged 50-79 years with varying 15-year colorectalcancer risk (1-7%).Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence.Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach.Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk
Occult Blood Detection Testing for Non-ColorectalCancer Related Medical Conditions: Clinical Effectiveness Occult Blood Detection Testing for Non-ColorectalCancer Related Medical Conditions: Clinical Effectiveness | CADTH.ca Find the information you need Occult Blood Detection Testing for Non-ColorectalCancer Related Medical Conditions: Clinical Effectiveness Occult Blood Detection Testing for Non-ColorectalCancer Related Medical Conditions: Clinical Effectiveness Last updated: April 15 (...) , 2019 Project Number: RA1026-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of the fecal immunochemical test in detecting medical conditions other than colorectalcancer where occult blood detection is needed? What is the clinical effectiveness of the guaiac fecal blood occult test in detecting medical conditions other than colorectalcancer where occult blood detection is needed? Key Message
Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic ColorectalCancer Funding Request Treatment of adult patients with mCRC who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission No NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada (...) Trifluridine and Tipiracil (Lonsurf) for Metastatic ColorectalCancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic ColorectalCancer Resubmission – Details | CADTH.ca Find the information you need Trifluridine and Tipiracil (Lonsurf) for Metastatic ColorectalCancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic ColorectalCancer Resubmission – Details Project Number pCODR 10173 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil
neoplasia. ATZ: anal transitional zone. BSG: British Society of Gastroenterology. BSGM: British society of genetic medicine. CHRPE: congenital hypertrophy retinal pigmentation epithelium. CI: confidence intervals. COX-2: Cyclooxygenase-2 . CRC: colorectalcancer. CSSC: Clinical Services and Standards Committee. EHTG: European Hereditary Tumour Group. EOCRC: Early onset CRC. ESGE: European Society of Gastrointestinal Endoscopy. FAP: Familial adenomatous polyposis. FDR: First-degree relative. FH: family (...) ; Strength of recommendation: strong) o We suggest that when abdominal-perineal excision can be avoided, a standard low anterior resection is a reasonable option to treat rectal cancers in LS patients, even though the residual colon is at high-risk of metachronous neoplasia. (GRADE of evidence: low; Strength of recommendation: weak) o We recommend that gastric, small bowel, or pancreatic surveillance in LS patients is only performed in the context of a clinical trial. (GRADE of evidence: low; Strength
Breast/Ovarian Hereditary Cancer Syndromes Cancers of Unknown Primary Site Cancers of Unknown Primary Site Endocrine and Neuroendocrine Cancers Neuroendocrine Bronchial and Thymic Tumours • Neuroendocrine Gastroenteropancreatic Tumours • Adrenal Cancer • Thyroid CancerGastrointestinalCancers Rectal Cancer • Biliary cancer • Gastric cancer • Oesophageal cancer • Cancer of the pancreas • Metastatic colorectalcancer • Anal cancer • Early coloncancer • Familial risk colorectalcancer • Hepatocellular (...) carcinoma Genitourinary Cancers Testicular Germ Cell Cancer • Cancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular Seminoma and Non-Seminoma Gynaecological Cancers Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer • Ovarian Cancer Haematological Malignancies Waldenstrom's macroglobulinaemia • Chronic myeloid leukaemia • Newly diagnosed and relapsed